What is the shelf life of DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER?

The shelf life of DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is determined by the manufacturer, Baxter International, and is indicated on the product packaging. It is typically dependent on the specific formulation and the integrity of the packaging, often ranging from 12 to 24 months under specified storage conditions.

Can DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER be mixed with other IV solutions?

Mixing DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER with other intravenous solutions is generally not recommended without specific clinical guidance. The compatibility of additives must be carefully assessed by healthcare professionals to prevent precipitation, degradation, or adverse reactions. The manufacturer's product information provides guidance on potential incompatibilities.

What are the common adverse effects associated with dextrose-based parenteral nutrition?

Common adverse effects of dextrose-based parenteral nutrition can include hyperglycemia or hypoglycemia, electrolyte imbalances (e.g., hyperkalemia, hyponatremia), fluid overload, infusion site reactions (e.g., phlebitis, infection), and gastrointestinal intolerance upon refeeding. Careful monitoring by healthcare providers is essential to manage these risks.

How is DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER administered?

DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is administered intravenously via a central venous catheter or a peripheral venous catheter, depending on the patient's needs, the concentration of the solution, and the duration of therapy. Administration requires sterile technique and is performed by trained healthcare professionals.

What distinguishes DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER from other parenteral nutrition products?

DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is a specific formulation that includes dextrose as its primary carbohydrate source and essential electrolytes, provided in a ready-to-use plastic container. Its differentiation from other PN products lies in its specific ingredient profile, osmolarity, pH, and packaging. Other PN products may offer different carbohydrate sources (e.g., amino acids as primary calories), varying electrolyte compositions, lipid emulsions, or different container types (e.g., multi-chamber bags, glass bottles).

When will the patents on DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER expire, and when will generic DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Medcl	DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	018379-007	Jun 24, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER, a parenteral nutrition solution, operates within the specialized market of intravenous feeding. Its market presence is influenced by the prevalence of conditions requiring nutritional support, the evolving healthcare infrastructure, and regulatory frameworks governing such medical products. Financial performance is directly tied to sales volumes, pricing strategies, manufacturing costs, and the competitive landscape.

What is DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER?

DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is a ready-to-use intravenous solution. It provides a combination of dextrose, an energy source, and electrolytes, administered parenterally to patients unable to receive adequate nutrition orally or enterally. The product is packaged in a plastic container designed for sterile infusion. Its primary use case is in clinical settings for patients experiencing malnutrition, gastrointestinal dysfunction, or critical illness requiring nutritional support.

What are the Key Therapeutic Areas and Patient Populations?

The primary therapeutic area for DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is parenteral nutrition (PN). This is indicated for patients requiring nutritional support due to:

Gastrointestinal Malabsorption: Conditions such as short bowel syndrome, Crohn's disease, and ulcerative colitis that impair nutrient absorption.
Intestinal Obstruction or Ileus: Where the normal passage of food through the digestive tract is blocked or significantly slowed.
Critical Illness: Patients in intensive care units (ICUs) with severe burns, sepsis, or multi-organ failure, who have increased metabolic demands and compromised gut function.
Pre- and Post-Surgical Patients: Individuals undergoing major surgeries, especially those involving the gastrointestinal tract, who may not be able to eat for extended periods.
Cancer Patients: Particularly those undergoing chemotherapy or radiation therapy that causes nausea, vomiting, or mucositis, impacting oral intake.
Premature Infants: Neonates with underdeveloped digestive systems requiring specialized nutritional support.

The patient population is diverse, encompassing all age groups from neonates to geriatrics, united by the common need for intravenous nutritional supplementation.

What is the Current Market Size and Growth Trajectory?

The global parenteral nutrition market, within which DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER operates, is projected to experience steady growth. Market research reports estimate the global PN market size to be approximately USD 6.5 billion in 2022, with projections indicating a compound annual growth rate (CAGR) of 5.0% to 7.0% through 2030 [1]. This growth is driven by:

Increasing Incidence of Chronic Diseases: A rise in conditions like cancer, inflammatory bowel disease, and metabolic disorders that necessitate PN.
Aging Global Population: Older individuals are more susceptible to malnutrition and conditions requiring nutritional support.
Advancements in PN Formulations and Delivery Systems: Innovations leading to improved efficacy and patient outcomes.
Expanding Healthcare Access: Growing healthcare infrastructure and expenditure in emerging economies.

Specific market data for DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is proprietary to the manufacturer, Baxter International. However, its market share within the broader PN market is contingent on its competitive positioning against other dextrose-based PN solutions and multi-chamber bags.

Who are the Key Competitors?

The market for dextrose-based PN solutions is competitive. Key competitors and their relevant product portfolios include:

Baxter International: As the manufacturer of DELFLEX, Baxter is a primary player. Their portfolio includes other PN solutions and components.
Fresenius Kabi: A significant competitor offering a wide range of IV drugs, medical devices, and nutritional therapies, including various PN formulations.
B. Braun Melsungen AG: Another major global healthcare company with a comprehensive offering in infusion therapy and clinical nutrition.
Nestlé Health Science: Offers specialized nutritional products, including some for critical care and disease-specific needs.
Grifols, S.A.: Provides plasma-derived medicines and other healthcare solutions, with some overlap in critical care nutrition.

Competition is based on product efficacy, safety profile, ease of use, cost-effectiveness, and the ability to meet evolving clinical guidelines and patient needs.

What is the Regulatory Landscape?

DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is subject to stringent regulatory oversight by health authorities worldwide. In the United States, this includes the Food and Drug Administration (FDA). Key regulatory considerations include:

Good Manufacturing Practices (GMP): Ensuring consistent quality and safety of the manufacturing process.
Product Approval and Labeling: Compliance with FDA requirements for drug product approval, including efficacy and safety data, and accurate product labeling.
Pharmacopeial Standards: Adherence to standards set by the United States Pharmacopeia (USP) for drug quality, purity, and strength. For example, USP <71> Sterility Tests and USP <85> Bacterial Endotoxins Tests are critical.
Adverse Event Reporting: Manufacturers are required to monitor and report adverse events associated with their products.
Supply Chain Security: Regulations aimed at ensuring the integrity and security of the pharmaceutical supply chain.

In Europe, the European Medicines Agency (EMA) and national regulatory bodies oversee product approval and manufacturing. Similar regulatory frameworks exist in other major markets, impacting market access and commercialization strategies.

What are the Manufacturing and Supply Chain Considerations?

The manufacturing of sterile parenteral nutrition solutions like DELFLEX involves specialized facilities and processes to maintain aseptic conditions. Key considerations include:

Aseptic Manufacturing: Production must occur in sterile environments using validated processes to prevent microbial contamination.
Raw Material Sourcing: High-quality dextrose, electrolytes, and other excipients must be sourced from approved suppliers.
Quality Control: Rigorous testing at various stages of production, including raw materials, in-process samples, and finished products, for purity, potency, sterility, and absence of pyrogens.
Packaging Integrity: The plastic container and sealing mechanisms must maintain product sterility and prevent leaks or contamination during storage and transport.
Cold Chain Management: Depending on the specific formulation and stability, temperature-controlled storage and transportation may be required.
Distribution Network: Establishing reliable distribution channels to hospitals, clinics, and infusion centers, ensuring timely delivery and product integrity.

The supply chain is vulnerable to disruptions from raw material shortages, manufacturing issues, or logistical challenges, which can impact product availability and pricing.

What is the Pricing Strategy and Reimbursement Landscape?

Pricing for DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is influenced by manufacturing costs, competitive pricing, and the perceived value in clinical practice. As a life-sustaining therapy, pricing often reflects the specialized nature of its production and its critical role in patient care.

The reimbursement landscape is complex and varies by country. In the United States, reimbursement is typically through:

Medicare and Medicaid: Government programs covering eligible patients, with specific reimbursement rates and policies for inpatient and outpatient services.
Private Health Insurance: Commercial payers reimburse for PN therapy based on established benefit plans, often requiring prior authorization.
Hospital Chargemaster: Hospitals bill for the product and associated services, with reimbursement rates negotiated with payers.

The classification of PN therapy under healthcare coding systems (e.g., ICD-10-CM for diagnosis, CPT codes for procedures) and drug pricing regulations are critical factors. Reimbursement rates directly impact the profitability of the product for the manufacturer and its accessibility for healthcare providers.

What are the Financial Projections and Key Performance Indicators?

Financial projections for DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER are integrated into Baxter International's overall financial reporting. Key performance indicators (KPIs) that would inform its financial trajectory include:

Sales Volume: The number of units sold globally, segmented by region or healthcare channel.
Revenue: Total income generated from sales.
Gross Profit Margin: Revenue minus the cost of goods sold, indicating manufacturing and supply chain efficiency.
Market Share: DELFLEX's percentage of the total dextrose-based PN market.
Customer Acquisition Cost: The expense associated with securing new hospital or clinic accounts.
Return on Investment (ROI): For any capital expenditures related to production or market development.

While specific financial data for DELFLEX is not publicly disclosed, Baxter International's annual reports provide insights into the performance of its broader nutrition business segment, which includes parenteral nutrition products. Trends in this segment, such as revenue growth or decline, provide an indicator of the overall market health for products like DELFLEX.

What are the Future Market Trends and Opportunities?

Future market trends and opportunities for DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER are shaped by advancements in medical science and healthcare delivery.

Personalized Nutrition: Increasing demand for tailored PN formulations based on individual patient metabolic profiles, genetics, and clinical conditions.
Home Parenteral Nutrition (HPN): Growth in HPN services enables patients to receive PN at home, managed by specialized home health agencies. This expands the market beyond hospital settings.
Advanced Delivery Systems: Development of smart infusion pumps and integrated monitoring systems that enhance safety and efficiency of PN administration.
Focus on Gut Health: Research into the role of the gut microbiome and its potential influence on PN strategies.
Cost Containment Pressures: Healthcare systems globally are seeking to reduce costs, which may drive demand for more cost-effective PN solutions or alternative therapies.
Emerging Markets: Expansion of healthcare access and infrastructure in developing countries presents significant growth opportunities.

Opportunities exist in developing more advanced formulations, exploring novel delivery methods, and optimizing manufacturing processes to reduce costs and improve sustainability.

Key Takeaways

DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is a critical component of the parenteral nutrition market. Its financial performance is driven by demand from patients requiring intravenous nutritional support due to gastrointestinal disorders, critical illness, and surgical interventions. The market is characterized by steady growth, influenced by an aging global population and the rising incidence of chronic diseases. Competition is robust, with major pharmaceutical and medical device companies vying for market share. Regulatory compliance is paramount, with stringent FDA and EMA guidelines governing manufacturing and product approval. Future growth hinges on advancements in personalized nutrition, home parenteral nutrition, and the expansion into emerging markets, while cost containment remains a significant market dynamic.

FAQs

What is the shelf life of DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER? The shelf life of DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is determined by the manufacturer, Baxter International, and is indicated on the product packaging. It is typically dependent on the specific formulation and the integrity of the packaging, often ranging from 12 to 24 months under specified storage conditions.
Can DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER be mixed with other IV solutions? Mixing DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER with other intravenous solutions is generally not recommended without specific clinical guidance. The compatibility of additives must be carefully assessed by healthcare professionals to prevent precipitation, degradation, or adverse reactions. The manufacturer's product information provides guidance on potential incompatibilities.
What are the common adverse effects associated with dextrose-based parenteral nutrition? Common adverse effects of dextrose-based parenteral nutrition can include hyperglycemia or hypoglycemia, electrolyte imbalances (e.g., hyperkalemia, hyponatremia), fluid overload, infusion site reactions (e.g., phlebitis, infection), and gastrointestinal intolerance upon refeeding. Careful monitoring by healthcare providers is essential to manage these risks.
How is DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER administered? DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is administered intravenously via a central venous catheter or a peripheral venous catheter, depending on the patient's needs, the concentration of the solution, and the duration of therapy. Administration requires sterile technique and is performed by trained healthcare professionals.
What distinguishes DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER from other parenteral nutrition products? DELFLEX w/ DEXTROSE 3.5% IN PLASTIC CONTAINER is a specific formulation that includes dextrose as its primary carbohydrate source and essential electrolytes, provided in a ready-to-use plastic container. Its differentiation from other PN products lies in its specific ingredient profile, osmolarity, pH, and packaging. Other PN products may offer different carbohydrate sources (e.g., amino acids as primary calories), varying electrolyte compositions, lipid emulsions, or different container types (e.g., multi-chamber bags, glass bottles).

Citations

[1] Global parenteral nutrition market size, share, and industry trends analysis report by product (amino acids, vitamins, trace elements, lipids, carbohydrates), by route of administration (intravenous, subcutaneous), by end-use (hospitals, long-term care facilities, home care, academic/research institutions), and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), market forecast 2023-2030. (n.d.). Grand View Research. Retrieved from https://www.grandviewresearch.com/industry-analysis/parenteral-nutrition-market

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER at DailyMed

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Delflex W/ Dextrose 3.5% In Plastic Container, and when can generic versions of Delflex W/ Dextrose 3.5% In Plastic Container launch?

AI Deep Research

Questions you can ask:

Summary for DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

US Patents and Regulatory Information for DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER: Market Dynamics and Financial Trajectory